IDH Antibodies

IDH Antibodies

Human isocitrate dehydrogenases (IDHs) are classified into three subtypes: IDH1, IDH2 and IDH3. Mutant forms of IDH1 appear in 90% of patients with glioma while the mutant forms of IDH2 appear in 50% of patients, making IDH1/2 mutations a useful marker for prognosis of glioma. MBLI offers highly specific IDH antibodies to mutant forms of IDH1 (R132H, R132S, R132G) and IDH2 (R172K, R172M, R172W) which can be used to detect mutated IDHs in specimens of low tumour occupancy.

Isocitrate dehydrogenase 1 (IDH1) mutations, which have been identified as early and frequent genetic alterations in astrocytomas, oligodendrogliomas, and oligoastrocytomas, as well as in secondary glioblastomas, might be the initiating event in these glioma subtypes. In contrast, primary glioblastomas, as well as other systemic cancers, rarely contain IDH1 mutations. The IDH1 mutations are remarkably specific to a single codon in the conserved and functionally important Arginine 132 residue (R132) in IDH1.
Mutations in the analogous IDH2-R172 codon also occur at a lower rate in these cancers. IDH1/2 mutations were observed subsequently in 22% of acute myeloid leukemias. IDH1 mutations were found to result in the ability of the enzyme to catalyze the reduced NADP-dependent reduction of α-ketoglutarate to R(-)-2-hydroxyglutarate (2-HG). Reduction of α-ketoglutarate by 2-HG or mutant IDH1 results in a lower level of prolyl hydroxylases and promotes the accumulation of hypoxia-inducible factor (HIF) 1α. HIF-1α levels were greater in human gliomas harboring an IDH1 mutation than in tumors without the mutation. IDH1 appears to function as a tumor suppressor that, when mutationally inactivated, contributes to tumorigenesis in part through induction of the HIF-1 pathway.

Anti-IDH1 Antbiodies:

Anti-IDH1-R132S mAb (SMab-1)
Anti-IDH1-R132G mAb (GMab-r1)
Anti-IDH1 mAb (RMab-3)
Anti-IDH1 mAb (RcMab-1)

Anti-IDH2 Antibodies:

Anti-IDH2 mAb (KrMab-3)
Anti-IDH2-R172K mAb (KMab-1)
Anti-IDH2-R17M mAb (MMab-1)
Anti-IDH2-R172W mAb (WMab-1)

Caltag Medsystems is the distributor of MBLI’s products in the UK and Ireland. If you have any questions about these products, please contact us.

To view our full list of IDH products, please click here

IDH Antibodies

Contact us